Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

Supporting evidence

• Evaluation report

• Draft guidance committee papers (PDF 12.35 MB)

  Published:

  06 March 2024

• Final guidance committee papers (PDF 3.12 MB)

  Published:

  06 March 2024